Associate Professor, Psychiatry-Massachusetts General Hospital, Harvard Medical School
Psychiatry
Dr. David C. Henderson, MD
|
|
Give Review
David C. Henderson works in the field of Psychiatry. He went to University of Massachusetts Medical School. University of Massachusetts Medical School is ranked 49 in research and 12 in primary care medicine He received awards:"Super Doctor". David C. Henderson is a published doctor and has 92 publications published. The lastest was: 'Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Delineating responsibility: primary care provider perspective.
- A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in Schizophrenia patients: Effect on inflammation, psychopathology, cognition and l...
- Understanding cohort differences in appraisals of reconstruction priorities of Mental health systems in postconflict Liberia.
- Cancer care for individuals with Schizophrenia.
- Assessment of the needs of vulnerable youth populations in post-conflict Liberia.
- Open-label pilot study on vitamin D3 supplementation for antipsychotic-associated metabolic anomalies.
- No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with Schizophrenia.
- An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in Schizophrenia patients treated with atypical antipsychotics.
- No physical health without Mental health: lessons unlearned?
- Assessing the prospect of donepezil in improving cognitive impairment in patients with Schizophrenia.
- Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with Schizophrenia.
- Atypical antipsychotics are associated with incident diabetes in older adults without Schizophrenia or bipolar disorder.
- Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with Schizophrenia.
- Becoming adherent to antipsychotics: a qualitative study of treatment-experienced Schizophrenia patients.
- Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with Schizophrenia.
- No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with Schizophrenia.
- Triglyceride/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic...
- Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with Schizophrenia on clozapine or risperidone.
- Modafinil for clozapine-treated Schizophrenia patients: a double-blind, placebo-controlled pilot trial.
- Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with Schizophrenia treated with clozapine but not olanzapine.
- Aripiprazole added to overweight and obese olanzapine-treated Schizophrenia patients.
- Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in Schizophrenia.
- Managing weight gain and metabolic issues in patients treated with atypical antipsychotics.
- Prolactin-related and metabolic adverse effects of atypical antipsychotic agents.
- Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in Schizophrenia.
- Considerations for inpatient versus outpatient treatment with antipsychotics.
- Hepatitis C in Schizophrenia: screening experience in a community-dwelling clozapine cohort.
- A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in Schizophrenia.
- Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in Schizophrenia patients receiving atypical antipsychotics.
- Weight gain with atypical antipsychotics: evidence and insights.
- Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic Schizophrenia patients.
- Treatment of cardiac risk factors among patients with Schizophrenia and diabetes.
- Glucose metabolism in patients with Schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model anal...
- Dietary intake profile of patients with Schizophrenia.
- Independent effects of tobacco abstinence and bupropion on cognitive function in Schizophrenia.
- Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
- Building primary care practitioners' attitudes and confidence in Mental health skills in a post-conflict society: a Cambodian example.
- A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in Schizophrenia.
- A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
- Modafinil-associated weight loss in a clozapine-treated Schizoaffective disorder patient.
- Medical morbidity and mortality in Schizophrenia: guidelines for psychiatrists.
- Schizophrenia and comorbid metabolic disorders.
- Glucose metabolism in patients with Schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model...
- Attitudes of Schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.
- Folate, homocysteine, and negative symptoms in Schizophrenia.
- Clozapine and hypertension: a chart review of 82 patients.
- Two-year follow-up of a smoking cessation trial in patients with Schizophrenia: increased rates of smoking cessation and reduction.
- Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with Schizophrenia.
- Low-dose clozapine and diabetic ketoacidosis.
- Developing novel treatments for mood Disorders: accelerating discovery.
- Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents.
- Schizophrenia and diabetes.
- Capacity building in global Mental health: professional training.
- Phenotypic characteristics in metabolically obese but normal weight non-diabetic patients with Schizophrenia.
- Antipsychotic treatment associated with higher risk of hyperglycaemia in older persons with diabetes.
- Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with Schizophrenia.
- Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic Schizophrenia.
- Analysis of peripheral immune activation in Schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR).
- Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with Schizophrenia.
- Sibutramine: current status as an anti-obesity Drug and its future perspectives.
- A placebo-controlled study of sildenafil effects on cognition in Schizophrenia.
- Posttraumatic stress disorder, cognitive function and quality of life in patients with Schizophrenia.
- Sexual functioning, psychopathology and quality of life in patients with Schizophrenia.
- Inflammation and Schizophrenia.
- Risperidone augmentation for Schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial.
- Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in Schizophrenia.
- Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with Schizophrenia.
- Psychiatric effects of traumatic brain injury events in Cambodian survivors of mass violence.
- Added donepezil for stable Schizophrenia: a double-blind, placebo-controlled trial.
- A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in Schizophrenia patients.
- Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?
- A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with Schizophrenia.
- Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
- Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories.
- Risperidone added to clozapine: impact on serum prolactin levels.
- Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
- Cigarette smoking in Schizophrenia: relationship to psychopathology and medication side effects.
- Switching from clozapine to olanzapine in treatment-refractory Schizophrenia: safety, clinical efficacy, and predictors of response.
- Fronto-hippocampal function during temporal context monitoring in Schizophrenia.
- Clozapine: diabetes mellitus, weight gain, and lipid abnormalities.
- Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents.
- Clozapine for polydipsia and hyponatremia in chronic schizophrenics.
- Metabolic and endocrine disturbances in psychiatric Disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
- A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
- An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic Schizophrenia.
- A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia.
- Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic Schizophrenia.
- Citalopram and clozapine: potential Drug interaction.
- Trimethoprim-sulfamethoxazole and clozapine.
- A high-density quantitative nuclease protection microarray platform for high throughput analysis of gene expression.
- Lithium to allow clozapine prescribing in benign ethnic neutropenia.
Schools
University of Massachusetts Worcester Campus
St Elizabeths Hospital
Massachusetts General Hospital
Conditions Treated
- Nondependent Drug and Alcohol Abuse
- Psychosis Due to Mental Illness
- Schizophrenia
- Schizophreniform and Schizoaffective Disorder
Doctors Specialties
- Psychiatry
Accepted Insurances
Awards
- Super Doctor
Education
-
Massachusetts General Hospital -
University of Massachusetts Medical School
Hospital
-
Massachusetts General Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Siobhan M. O'Neill, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca W. Brendel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane L. Erb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark J. Viron, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth J. Levey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diane V. Stevens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William E. Greenberg, MD |
|
|
Dr. Sabrina M. Popp, MD
This Doctor is OpenDoctor Recommended.
|